^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer

    Related cancers:
    1d
    A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    1d
    Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. (PubMed, Transl Oncol)
    In CEACAM5 HE, the ORR was greater with high versus low cCEA. Associations were observed between cCEA and cCEACAM5; IHC CEACAM5, cCEA, and cCEACAM5; IHC CEACAM5 and CEACAM5 mRNA, but not between IHC CEACAM5 and oncogenic drivers.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    tusamitamab ravtansine (SAR408701)
    2d
    Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF/PD-1(L1) therapy. (PubMed, Front Immunol)
    PD-1(L1)/VEGF BsAbs like ivonescimab represent a novel therapeutic strategy with potential for improved efficacy and mitigated toxicity compared to combination therapies. Ongoing trials will define broader applications.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Yidafan (ivonescimab)
    2d
    Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer (clinicaltrials.gov)
    P2, N=36, Active, not recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Active, not recruiting | Trial completion date: May 2030 --> Dec 2030 | Trial primary completion date: May 2025 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab)
    2d
    A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC (clinicaltrials.gov)
    P3, N=162, Terminated, Bio-Thera Solutions | N=676 --> 162 | Trial completion date: Oct 2028 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Jul 2027 --> Jul 2025; The new regulatory developments have led us to conclude that a Phase 3 study is no longer necessary for the development and approval of BAT3306. As such, to ensure effective use of clinical resources, we are terminating this study.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed
    3d
    A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2 trial
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • SYS6010
    6d
    STK-012-101: Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers (clinicaltrials.gov)
    P1/2, N=364, Recruiting, Synthekine | Phase classification: P1 --> P1/2 | N=202 --> 364 | Trial completion date: Oct 2027 --> Jan 2029 | Trial primary completion date: Oct 2027 --> Jan 2029
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • STK-012
    6d
    KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) (clinicaltrials.gov)
    P2, N=130, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • pemetrexed • MK-1084
    8d
    NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=327, Recruiting, UNICANCER | Active, not recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    8d
    KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)
    P2, N=102, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    8d
    Adjuvant Chemotherapy for High-Risk Pathologic Stage I Non-Squamous NSCLC (clinicaltrials.gov)
    P=N/A, N=2072, Completed, The First Affiliated Hospital with Nanjing Medical University
    New trial
    9d
    Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, National Cancer Institute (NCI) | N=85 --> 22 | Trial completion date: Jun 2026 --> Nov 2026 | Trial primary completion date: Jun 2026 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • BRAF V600K • KEAP1 mutation • NFE2L2 mutation
    |
    Guardant360® CDx • MSK-IMPACT
    |
    sapanisertib (CB-228) • telaglenastat (CB-839)